Glioma clinical trials in Minnesota
13 studies for Glioma are looking for participants at sites in Minnesota.
Cities in Minnesota
Medication Combinations of Dasatinib, Quercetin, Fisetin, Temozolomide, LMP744, and Autologous TLPO Vaccine for the Treatment of Previously Treated Glioma With Residual Disease
- Mayo Clinic in Rochester, Rochester
RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07025226A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
- Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis
- University of Minnesota/Masonic Cancer Center, Minneapolis
RecruitingPhase 1/2
12 Months – 21 Years · All sexes · Updated Oct 1, 2026 · NCT05099003SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Mayo Clinic - Rochester, Rochester
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT05303519Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)
- Children's Minnesota, Minneapolis
RecruitingPhase 1
Ages 1 to 25 · All sexes · Updated Aug 18, 2026 · NCT04485559Feasibility of Intra- and Post-operative Microdialysis During Neurosurgery for Central Nervous System Lesions
- Mayo Clinic in Rochester, Rochester
Recruiting
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT04047264A Digital Treatment Platform for the Delivery of Home-Based Sequential Therapy in Patients With Glioma, GHoST Trial
- Mayo Clinic in Rochester, Rochester
Recruiting
Ages 18 and older · All sexes · Updated Aug 10, 2026 · NCT07074756A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- St. Luke's Hospital, Duluth
RecruitingPhase 2
Ages 8 and older · All sexes · Updated Jul 27, 2026 · NCT05503797Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas
- Mayo Clinic in Rochester, Rochester
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 24, 2026 · NCT07468136Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab
- Mayo Clinic, Rochester
RecruitingPhase 1/2
Ages 19 and older · All sexes · Updated Jun 8, 2026 · NCT06011109Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- Mayo Clinic Cancer Center, Rochester
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Apr 13, 2026 · NCT06810544Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.
- Mayo Clinic in Rochester, Rochester
RecruitingPhase 1
Ages 18 to 75 · All sexes · Updated Mar 24, 2026 · NCT06482905Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma
- Mayo Clinic in Rochester, Rochester
RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated Nov 4, 2025 · NCT05717153CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults
- Children's Minnesota, Minneapolis
RecruitingPhase 1
Ages 2 to 25 · All sexes · Updated Mar 12, 2024 · NCT06305910From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.